Plus   Neg

Revance Therapeutics Inc. (RVNC) Has Surged To A New High On Study Results

Revance Therapeutics Inc. (RVNC) announced Tuesday morning that its two Phase 3 trials of RT002 injection met their primary and all secondary endpoints in patients with Glabellar lines.

Revance Therapeutics has gapped open sharply higher this morning and is now up 8.92 at $34.92 on the highest volume of the year. The stock has broken out of a 2-month trading range and has set a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT